You’re a pinch-hitter at an away game—the second in a double header—and you’re up to bat after the last pitch resulted in an eye-popping homerun. Six thousand are watching. Oh, and hundreds of millions of dollars are at stake.
That’s somethings similar the situation that confronted Seeger Weiss partner David Buchanan on the eve of the latest trial over the testosterone replacement therapy AndroGel, which ended last week with a $140 million verdict in punitive damages against Abbott Laboratories spin-off AbbVie.
